Abogen Announces Licensing and Option Agreement with Novartis to Advance mRNA-Encoded T-Cell Engager and other potential RNA programs (PRNewswire) - Oct 2, 2026 - "The agreement includes an exclusive worldwide license to Abogen's lead asset, ABO2203, as well as options to exclusively license other potential programs leveraging Abogen's proprietary RNA platform. ABO2203 is a novel mRNA-encoded CD19xCD3 T-cell engager with the potential to transform the treatment landscape for patients with autoimmune diseases....Under the agreement, Novartis will also have the exclusive option to license a number of next-generation therapeutic assets developed on Abogen's RNA platform."
Licensing / partnership • Immunology
|